irofulven + prednisolone

Irofulven + prednisolone is a combination drug regimen used primarily in clinical trials for metastatic castration-resistant prostate cancer (mCRPC) that has progressed after prior therapies, including androgen receptor-targeted agents and docetaxel. Irofulven is a semisynthetic derivative of illudin S, functioning as a DNA alkylating agent that binds DNA and induces cytotoxicity by DNA damage and inhibition of replication. Prednisolone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, commonly used to manage symptoms and adverse effects of cancer treatments. The combination aims to improve antitumor activity and tolerance compared with alternative regimens in docetaxel-pretreated prostate cancer. Irofulven is administered intravenously (e.g., 0.45 mg/kg on days 1 and 8 of a three-week cycle), and prednisolone is administered orally (10 mg daily)[1][2][4][5].

Other names

6-hydroxymethylacylfulveneHMAFirofulvenprednisolone